Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Microdose α-interferon shows clinical and antiangiogenic effect in extramedullary myeloid tumor: a case report

Leukemia volume 17, pages 986–987 (2003)Cite this article

TO THE EDITOR

Extramedullary myeloid tumors (EMMT) are peculiar neoplasms that derive from myeloid progenitors, onset as solid masses in different tissues, involving bone marrow and peripheral blood only at the latest stages of progression.1 The prognosis is strictly related to a correct diagnosis and a prompt intervention with a fitting treatment. In fact, patients are curable when treated early with conventional regimens for acute myeloid leukemias (AML); unfortunately, however, the initial diagnosis is frequently not correct and the appropriate treatment is delayed, with subsequent unsatisfactory results. Bone marrow transplantation (BMT) is probably the only curative approach in lately diagnosed cases, but it is rarely suitable for the high toxicity; new strategies are thus warranted in order to improve the outcome.1,2

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Byrd JC, Edenfield WJ, Shields DJ, Dawson NA . Extramedullary myeloid cell tumors in acute non lymphocytic leukemia: a clinical review. J Clin Oncology 1995; 13: 1800–1816.

    Article  CAS  Google Scholar 

  2. Menasce LP, Banerjee SS, Beckett E, Harris M . Extra-medullary myeloid tumour (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases. Histopathology 1999; 34: 391–398.

    Article  CAS  Google Scholar 

  3. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81: 1398–1401.

    Article  CAS  Google Scholar 

  4. Aguayo A, Estey E, Kantarjan H, Manshouri T, Gidel C, Keating M . Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717–3721.

    CAS  Google Scholar 

  5. Hussong JW, Rodgers GM, Shami PJ . Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309–313.

    CAS  Google Scholar 

  6. Marler JJ, Rubin JB, Trede NS, Connors S, Grier H, Upton J . Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 2002; 109: E37.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by AIL Pesaro ONLUS.

Author information

Authors and Affiliations

  1. Department of Hematology, S. Salvatore Hospital, Pesaro, Italy

    P P Piccaluga, G Visani, A Isidori & M Malagola

  2. University of Bologna, Bologna, Italy

    S Ascani & S A Pileri

Authors
  1. P P Piccaluga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Visani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Isidori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Malagola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Ascani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S A Pileri
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piccaluga, P., Visani, G., Isidori, A. et al. Microdose α-interferon shows clinical and antiangiogenic effect in extramedullary myeloid tumor: a case report. Leukemia 17, 986–987 (2003). https://doi.org/10.1038/sj.leu.2402904

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402904

This article is cited by

Search

Advanced search

Quick links